[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 400587
1. Chen WC, Wang Z, Missinato MA, Park DW, Long DW, Liu HJ, Zeng X, Yates NA, Kim K, Wang Y: Decellularized zebrafish cardiac extracellular matrix induces mammalian heart regeneration. Sci Adv; 2016 Nov;2(11):e1600844
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decellularized zebrafish cardiac extracellular matrix induces mammalian heart regeneration.
  • Heart attack is a global health problem that leads to significant morbidity, mortality, and health care burden.
  • Adult human hearts have very limited regenerative capability after injury.
  • Mammalian cardiac ECM may not be optimally inductive for cardiac regeneration because of the fibrotic, instead of regenerative, responses in injured adult mammalian hearts.
  • Given the high regenerative capacity of adult zebrafish hearts, we hypothesize that decellularized zebrafish cardiac ECM (zECM) made from normal or healing hearts can induce mammalian heart regeneration.
  • Using zebrafish and mice as representative species of lower vertebrates and mammals, we show that a single administration of zECM, particularly the healing variety, enables cardiac functional recovery and regeneration of adult mouse heart tissues after acute myocardial infarction. zECM-treated groups exhibit proliferation of the remaining cardiomyocytes and multiple cardiac precursor cell populations and reactivation of ErbB2 expression in cardiomyocytes.
  • Furthermore, zECM exhibits pro-proliferative and chemotactic effects on human cardiac precursor cell populations in vitro.
  • These contribute to the structural preservation and correlate with significantly higher cardiac contractile function, notably less left ventricular dilatation, and substantially more elastic myocardium in zECM-treated hearts than control animals treated with saline or decellularized adult mouse cardiac ECM.
  • This study departs from conventional focuses on mammalian ECM and introduces a new approach for cardiac tissue regeneration.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Healthc Mater. 2015 Jul 15;4(10):1545-54 [25988681.001]
  • [Cites] ScientificWorldJournal. 2011 Jun 09;11:1270-99 [21666994.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1446-51 [23302686.001]
  • [Cites] Cell Stem Cell. 2012 Mar 2;10(3):244-58 [22385653.001]
  • [Cites] J Am Coll Cardiol. 2016 Mar 8;67(9):1074-86 [26940929.001]
  • [Cites] Nat Protoc. 2006;1(6):2856-60 [17406544.001]
  • [Cites] Annu Rev Cell Dev Biol. 2012;28:719-41 [23057748.001]
  • [Cites] J Biol Chem. 1993 May 25;268(15):11134-42 [8098709.001]
  • [Cites] Sci Transl Med. 2013 Feb 20;5(173):173ra25 [23427245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8850-5 [24876275.001]
  • [Cites] Biomaterials. 2015 Mar;45:56-63 [25662495.001]
  • [Cites] J Mol Cell Cardiol. 2010 Mar;48(3):474-82 [19729019.001]
  • [Cites] Development. 2016 Mar 1;143(5):729-40 [26932668.001]
  • [Cites] Sci Transl Med. 2015 Apr 1;7(281):281ra45 [25834111.001]
  • [Cites] Acta Biomater. 2014 Jan;10(1):194-204 [24012606.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):340-9 [14647453.001]
  • [Cites] Stem Cells. 2015 Feb;33(2):557-73 [25336400.001]
  • [Cites] Nature. 2013 Jan 17;493(7432):433-6 [23222518.001]
  • [Cites] Curr Opin Genet Dev. 2013 Aug;23(4):408-14 [23849799.001]
  • [Cites] Science. 2009 Apr 3;324(5923):98-102 [19342590.001]
  • [Cites] Dev Cell. 2016 Feb 22;36(4):362-74 [26906733.001]
  • [Cites] Birth Defects Res C Embryo Today. 2012 Dec;96(4):325-33 [24203921.001]
  • [Cites] Cardiovasc Res. 2015 Sep 1;107(4):487-98 [26156497.001]
  • [Cites] Expert Opin Biol Ther. 2010 Dec;10(12):1717-28 [21058932.001]
  • [Cites] Nature. 1974 Mar 8;248(5444):145-7 [4818918.001]
  • [Cites] Elife. 2015 Apr 01;4:null [25830562.001]
  • [Cites] Nat Med. 2002 May;8(5):459-65 [11984589.001]
  • [Cites] N Engl J Med. 2012 Nov 29;367(22):2150-3 [23190227.001]
  • [Cites] Biomaterials. 2013 Feb;34(6):1747-56 [23211448.001]
  • [Cites] IEEE Trans Ultrason Ferroelectr Freq Control. 1999;46(1):82-96 [18238401.001]
  • [Cites] Annu Rev Cell Dev Biol. 2008;24:525-49 [18598212.001]
  • [Cites] Stem Cells. 2013 Feb;31(2):305-16 [23165704.001]
  • [Cites] Organogenesis. 2015;11(1):1-15 [25915734.001]
  • [Cites] Ann Biomed Eng. 2014 Jul;42(7):1517-27 [24402648.001]
  • [Cites] Nature. 2015 Apr 23;520(7548):445-6 [25903623.001]
  • [Cites] Nat Cell Biol. 2015 May;17 (5):627-38 [25848746.001]
  • [Cites] Cardiovasc Res. 2010 Jun 1;86(3):365-73 [20071355.001]
  • [Cites] J Biomed Mater Res A. 2015 Mar;103(3):1246-58 [24910444.001]
  • [Cites] Cell. 2009 Jul 23;138(2):257-70 [19632177.001]
  • [Cites] Cell. 2014 May 8;157(4):795-807 [24813607.001]
  • [Cites] J Cell Biochem. 2012 Jul;113(7):2217-22 [22415903.001]
  • [Cites] Circulation. 2015 Jul 14;132(2):109-21 [25995316.001]
  • [Cites] Science. 2002 Dec 13;298(5601):2188-90 [12481136.001]
  • [Cites] J Cardiovasc Transl Res. 2010 Oct;3(5):478-86 [20632221.001]
  • [Cites] PLoS One. 2012;7(6):e39066 [22720029.001]
  • [Cites] J Proteomics. 2015 Jan 15;113:29-37 [25277046.001]
  • [Cites] Ann Biomed Eng. 2016 Sep;44(9):2827-39 [26842626.001]
  • [Cites] Int J Dev Biol. 2012;56(6-8):567-76 [22689358.001]
  • [Cites] Cell Cycle. 2015 Aug 3;14(15):2383-4 [26083142.001]
  • [Cites] J Cell Biol. 1971 May 1;49(2):560-3 [19866784.001]
  • [Cites] PLoS Biol. 2006 Aug;4(8):e260 [16869712.001]
  • [Cites] Int J Biochem Cell Biol. 2014 Nov;56:47-55 [25450455.001]
  • [Cites] Nat Rev Mol Cell Biol. 2013 Aug;14(8):467-73 [23839578.001]
  • [Cites] J Am Soc Echocardiogr. 1995 Sep-Oct;8(5 Pt 1):602-10 [9417202.001]
  • [Cites] Biomaterials. 2010 Oct;31(30):7678-83 [20674011.001]
  • [Cites] Curr Opin Biotechnol. 2013 Oct;24(5):830-3 [23726156.001]
  • [Cites] Tissue Eng Part B Rev. 2013 Jun;19(3):194-208 [23083305.001]
  • [Cites] Heart. 1999 Aug;82(2):192-8 [10409535.001]
  • [Cites] Science. 2011 Feb 25;331(6020):1078-80 [21350179.001]
  • [Cites] Nature. 1998 May 21;393(6682):276-80 [9607766.001]
  • [Cites] PLoS One. 2013 Aug 23;8(8):e72388 [24058412.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):332-44 [17457301.001]
  • [Cites] Cardiovasc Res. 2014 May 1;102(2):312-20 [24623280.001]
  • [Cites] J Mol Cell Cardiol. 2016 Feb;91:228-37 [26778458.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H990-7 [25724498.001]
  • [Cites] Biomaterials. 2015 Dec;72 :138-51 [26370927.001]
  • [Cites] Dev Cell. 2008 Oct;15(4):521-33 [18854137.001]
  • (PMID = 28138518.001).
  • [ISSN] 2375-2548
  • [Journal-full-title] Science advances
  • [ISO-abbreviation] Sci Adv
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA047904; United States / NCRR NIH HHS / RR / S10 RR027383
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Extracellular matrix / cardiac repair / cardiomyogenesis / decellularization / heart regeneration / ischemic heart disease / myocardial infarction / zebrafish
  •  go-up   go-down


2. Kochegarov A, Lemanski LF: New Trends in Heart Regeneration: A Review. J Stem Cells Regen Med; 2016;12(2):61-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New Trends in Heart Regeneration: A Review.
  • : In this review, we focus on new approaches that could lead to the regeneration of heart muscle and the restoration of cardiac muscle function derived from newly-formed cardiomyocytes.
  • Various strategies for the production of cardiomyocytes from embryonic stem cells, induced pluripotent stem cells, adult bone marrow stem cells and cardiac spheres from human heart biopsies are described.
  • Pathological conditions which lead to atherosclerosis and coronary artery disease often are followed by myocardial infarction causing myocardial cell death.
  • After cell death, there is very little self-regeneration of the cardiac muscle tissue, which is replaced by non-contractile connective tissue, thus weakening the ability of the heart muscle to contract fully and leading to heart failure.
  • A number of experimental research approaches to stimulate heart muscle regeneration with the hope of regaining normal or near normal heart function in the damaged heart muscle have been attempted.
  • Some of these very interesting studies have used a variety of stem cell types in combination with potential cardiogenic differentiation factors in an attempt to promote differentiation of new cardiac muscle for possible future use in the clinical treatment of patients who have suffered heart muscle damage from acute myocardial infarctions or related cardiovascular diseases.
  • Although progress has been made in recent years relative to promoting the differentiation of cardiac muscle tissue from non-muscle cells, much work remains to be done for this technology to be used routinely in translational clinical medicine to treat patients with damaged heart muscle tissue and return such individuals to pre-heart-attack activity levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28096630.001).
  • [Journal-full-title] Journal of stem cells & regenerative medicine
  • [ISO-abbreviation] J Stem Cells Regen Med
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] India
  • [Keywords] NOTNLM ; Adult stem cells / Cardiac muscle regeneration / Embryonic stem cells / Induced pluripotent stem cells / Mesenchymal stem cells / MicroRNAs
  •  go-up   go-down


3. Chen YH, Chen YC, Liu CS, Hsieh MC: The Different Effects of Atorvastatin and Pravastatin on Cell Death and PARP Activity in Pancreatic NIT-1 Cells. J Diabetes Res; 2016;2016:1828071
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Statins have been widely used drugs for lowering low-density lipoprotein and for preventing heart attack and stroke.
  • The objective of this study was to elucidate the signaling pathway and biological function between necrosis and autophagy induced by atorvastatin (AS) and pravastatin (PS).
  • PARP1 exhibited a dual role in modulating necrosis and autophagy in AS- and PS-treated NIT-1 cells through RIP1-RIP3-MLKL pathway and PARP1-AMPK-mTOR pathway.
  • Lastly, AS treatment induced mitochondrial morphology injury significantly more than PS treatment did.


Advertisement
4. Pleines I, Woods J, Chappaz S, Kew V, Foad N, Ballester-Beltrán J, Aurbach K, Lincetto C, Lane RM, Schevzov G, Alexander WS, Hilton DJ, Astle WJ, Downes K, Nurden P, Westbury SK, Mumford AD, Obaji SG, Collins PW, Delerue F, Ittner LM, Bryce NS, Holliday M, Lucas CA, Hardeman EC, Ouwehand WH, Gunning PW, Turro E, Tijssen MR, Kile BT: Mutations in tropomyosin 4 underlie a rare form of human macrothrombocytopenia. J Clin Invest; 2017 Mar 01;127(3):814-829
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Platelet number and volume are independent risk factors for heart attack and stroke.
  • Here, we have identified 2 unrelated families in the BRIDGE Bleeding and Platelet Disorders (BPD) collection who carry a TPM4 variant that causes truncation of the TPM4 protein and segregates with macrothrombocytopenia, a disorder characterized by low platelet count.
  • N-Ethyl-N-nitrosourea-induced (ENU-induced) missense mutations in Tpm4 or targeted inactivation of the Tpm4 locus led to gene dosage-dependent macrothrombocytopenia in mice.
  • Together, our findings demonstrate a nonredundant role for TPM4 in platelet biogenesis in humans and mice and reveal that truncating variants in TPM4 cause a previously undescribed dominant Mendelian platelet disorder.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioarchitecture. 2011 Nov 1;1(6):284-289 [22545181.001]
  • [Cites] Adv Exp Med Biol. 2008;644:85-94 [19209815.001]
  • [Cites] Adv Exp Med Biol. 2008;644:232-49 [19209826.001]
  • [Cites] Nature. 2015 Oct 1;526(7571):82-90 [26367797.001]
  • [Cites] Am J Hum Genet. 2009 Jan;84(1):66-71 [19110211.001]
  • [Cites] Mol Cell Neurosci. 2014 Jan;58:11-21 [24211701.001]
  • [Cites] Trials. 2014 Sep 17;15:363 [25230735.001]
  • [Cites] Blood. 2011 Nov 24;118(22):5928-37 [21960593.001]
  • [Cites] Biochem J. 2014 Apr 1;459(1):1-13 [24627985.001]
  • [Cites] Science. 2014 Sep 26;345(6204):1251033 [25258084.001]
  • [Cites] Am J Hum Genet. 2013 Mar 7;92(3):431-8 [23434115.001]
  • [Cites] Blood. 2007 Jul 1;110(1):171-9 [17392504.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):e11-8 [23117662.001]
  • [Cites] Exp Cell Res. 2008 Feb 1;314(3):564-73 [18036591.001]
  • [Cites] Genetics. 1984 Oct;108(2):457-70 [6500258.001]
  • [Cites] Bioarchitecture. 2011 Jul;1(4):135-164 [22069507.001]
  • [Cites] Nature. 2011 Nov 30;480(7376):201-8 [22139419.001]
  • [Cites] J Thromb Haemost. 2011 Jul;9 Suppl 1:92-104 [21781245.001]
  • [Cites] J Muscle Res Cell Motil. 2015 Apr;36(2):147-53 [25369766.001]
  • [Cites] Blood. 2012 Mar 22;119(12):2906-13 [22174152.001]
  • [Cites] Methods Mol Biol. 2012;788:59-71 [22130700.001]
  • [Cites] Blood. 2015 Jul 23;126(4):520-30 [25964668.001]
  • [Cites] Nat Commun. 2014 Mar 17;5:3455 [24632563.001]
  • [Cites] Blood. 2015 Jan 29;125(5):869-72 [25361813.001]
  • [Cites] Sci Rep. 2016 Feb 05;6:20554 [26847712.001]
  • [Cites] Curr Biol. 2011 Apr 12;21(7):539-50 [21458264.001]
  • [Cites] Nature. 2016 Aug 17;536(7616):285-91 [27535533.001]
  • [Cites] Blood. 2015 Jan 29;125(5):860-8 [25411426.001]
  • [Cites] Physiol Rev. 2008 Jan;88(1):1-35 [18195081.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3348-54 [16322779.001]
  • [Cites] Blood. 2010 Sep 9;116(10):1767-75 [20530287.001]
  • [Cites] J Mol Cell Cardiol. 2010 May;48(5):893-8 [19835881.001]
  • [Cites] Genome Med. 2015 Apr 09;7(1):36 [25949529.001]
  • [Cites] J Cell Biol. 2013 Jun 10;201(6):785-96 [23751492.001]
  • [Cites] Mol Biol Cell. 2009 Jan;20(1):400-9 [19005216.001]
  • [Cites] Curr Opin Hematol. 2011 May;18(3):133-8 [21372707.001]
  • [Cites] J Thromb Haemost. 2011 Jul;9 Suppl 1:246-57 [21781261.001]
  • [Cites] PLoS One. 2013 Sep 17;8(9):e74728 [24069336.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1925-32 [16293600.001]
  • [Cites] PLoS Genet. 2014 Jul 10;10(7):e1004450 [25010335.001]
  • [Cites] Circ Res. 1997 Dec;81(6):1005-10 [9400381.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] Immunity. 2012 Dec 14;37(6):1009-23 [23219391.001]
  • [Cites] Curr Opin Hematol. 2007 Sep;14(5):419-26 [17934346.001]
  • [Cites] Blood. 2011 Aug 25;118(8):2285-95 [21652675.001]
  • [Cites] J Thromb Haemost. 2009 Jul;7 Suppl 1:272-6 [19630815.001]
  • [Cites] Blood. 2011 Mar 3;117(9):2718-27 [21156842.001]
  • [Cites] Br J Haematol. 2011 Jul;154(2):161-74 [21542825.001]
  • [Cites] J Cell Sci. 2015 Aug 15;128(16):2965-74 [26240174.001]
  • [Cites] EMBO J. 2012 Feb 15;31(4):1028-40 [22157816.001]
  • [Cites] Nat Protoc. 2013 Nov;8(11):2281-308 [24157548.001]
  • [Cites] Dev Cell. 2011 May 17;20(5):597-609 [21571218.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(6):2318-23 [14993271.001]
  • [Cites] Nat Protoc. 2007;2(5):1206-15 [17546016.001]
  • (PMID = 28134622.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / / RP-PG-0310-1002; United Kingdom / Medical Research Council / / MR/K023489/1; United Kingdom / Medical Research Council / / MC/ UP/ 0801/1; United Kingdom / British Heart Foundation / / RG/09/012/28096; United Kingdom / British Heart Foundation / / PG/13/77/30375
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Majid AR, Javad RM, Malihe P, Javad M: Scale-up production and characterization of anti-human cardiac troponin I monoclonal antibody in ascitic fluid of balb/c mice. J Immunoassay Immunochem; 2016 Dec 27;:1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scale-up production and characterization of anti-human cardiac troponin I monoclonal antibody in ascitic fluid of balb/c mice.
  • : The Human Cardiac Troponin I (hcTnI) is a 210 amino acid protein, 23 kDa in molecular weight.
  • This biomarker is commonly used to diagnose myocardial infarction, micro injury, and acute coronary syndrome (ACS) in patients referring to emergency departments.
  • The American Heart Association (AHA) and European Society of Cardiology (ESC) proposed troponin I as the gold biomarker for early detection of heart attack, especially in myocardial infarction (MI).
  • Therefore, developing monoclonal antibodies against this biomarker could help in for early detection of heart attack.
  • The aim of this study was to produce large scale of monoclonal antibody against human cardiac troponin I using Hybridoma technology in order to design a diagnostic kit.
  • The monoclonal antibody was produced using conventional Hybridoma technology in ascitic fluid of mouse and characterized for its ability to detect Human Cardiac Troponin I in a rapid test system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28026995.001).
  • [ISSN] 1532-4230
  • [Journal-full-title] Journal of immunoassay & immunochemistry
  • [ISO-abbreviation] J Immunoassay Immunochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; ascitic fluid / early detection / human cardiac troponin I / hybridoma technology
  •  go-up   go-down


6. Daily aspirin use to help prevent heart attacks could prove harmful. Nurs Stand; 2012 Feb 08;26(23):14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Daily aspirin use to help prevent heart attacks could prove harmful.
  • : Healthy people who regularly take aspirin in the hope of preventing a stroke or heart attack may do themselves more harm than good, according to a major international study led by UK researchers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28044541.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Iles-Smith H, Deaton C, Campbell M, Mercer C, McGowan L: The experiences of Myocardial Infarction patients readmitted within six months of Primary Percutaneous Coronary Intervention. J Clin Nurs; 2017 Jan 02;
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The experiences of Myocardial Infarction patients readmitted within six months of Primary Percutaneous Coronary Intervention.
  • AIM AND OBJECTIVES: This study explored the experiences of patients readmitted due to potential ischaemic heart disease (p-IHD) symptoms within 6 months of Primary Percutaneous Coronary Intervention (PPCI).
  • BACKGROUND: Following myocardial infarction (MI) and PPCI, some patients experience p-IHD symptoms that may lead to readmission.
  • Symptoms may be related to cardiac ischaemia, reduced psychological health or a comorbid condition.
  • This is the qualitative part of a mixed methods study.
  • METHODS: Participants were purposefully selected and concurrent sampling, data collection and data analysis were used.
  • RESULTS: Twenty-five participants (14 men, 27-79 years) experienced 1 to 4 readmissions; discharge diagnoses were cardiac, psychological, indeterminate, pulmonary and gastric.
  • 1) Anxiety, uncertainty and inability to determine cause of symptoms, 2) Fear of experiencing further MI, and 3) Insufficient opportunity to validate self-construction of illness.
  • RELEVANCE TO CLINICAL PRACTICE: Fear of dying or experiencing a further MI led to patients seeking help at the time of p-IHD symptoms.
  • Participants were anxious and lacked understanding regarding symptom attribution at the time of readmission and generally following their heart attack.
  • Additionally, original heart attack symptoms were used as a comparator for future symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 28042893.001).
  • [ISSN] 1365-2702
  • [Journal-full-title] Journal of clinical nursing
  • [ISO-abbreviation] J Clin Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Watanabe S: Low-protein diet for the prevention of renal failure. Proc Jpn Acad Ser B Phys Biol Sci; 2017;93(1):1-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of chronic kidney disease (CKD) is estimated to be 8-16% worldwide, and it is increasing.
  • CKD is a risk factor for heart attack and stroke, and it can progress to kidney failure requiring dialysis or transplantation.
  • A low-protein diet (less than 0.5 g/kg b.wt.) is a very effective intervention.
  • Low-protein rice (1/10 to 1/25 of the normal protein contents) is helpful to control the consumption of proteins, decreasing at the same time the intake of potassium and phosphate.Protein restriction is indicated as soon as the eGFR becomes lower than 60 ml/min/1.73 m<sup>2</sup> body surface, in order, to slow disease progression.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28077806.001).
  • [ISSN] 1349-2896
  • [Journal-full-title] Proceedings of the Japan Academy. Series B, Physical and biological sciences
  • [ISO-abbreviation] Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


9. Calcium supplements linked to myocardial infarction, but not stroke or CVD mortality. Nurs Stand; 2012 Jun 20;26(42):16-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium supplements linked to myocardial infarction, but not stroke or CVD mortality.
  • : Calcium supplements increase the risk of heart attack, according to a study that adds to the evidence that nutritional supplements should be taken with caution.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28055544.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Newnham D: Outside in - David Newnham fears life behind the wheel is fraught with hazard. Nurs Stand; 2010 Aug 11;24(49):26-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Every year my GP measures me up, sits me down and tells me whether I am more or less likely than Mr Average to suffer a stroke or heart attack.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28041107.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement